Wells Fargo lowered the firm’s price target on Autolus Therapeutics (AUTL) to $6 from $8 and keeps an Overweight rating on the shares. With Aucatzyl launch still in early phase, the firm thinks the main near-term focus is the initial SLE readout on April 23, where it believes a key factor to consider when interpreting data and comparing across datasets is existing tissue damage at baseline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects
- Autolus Therapeutics Reports Strong 2024 Results
- Optimistic Buy Rating for Autolus Therapeutics Driven by Strategic Advancements and Successful Launch of Aucatzyl
- Positive Outlook for Autolus Therapeutics Amidst Strategic Developments and Financial Strength
- Autolus Therapeutics Launches AUCATZYL® in U.S. Market
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue